- Sex- and migration-related differences in viral suppression and life expectancy among people with HIV: The PISCIS cohort, 1998-2023. [Journal Article]HIV Med. 2026 Oct 22. [Online ahead of print]HM
- CONCLUSIONS: Viral suppression and life expectancy improved substantially across all sex-migration groups over 26 years. However, differences in time to viral suppression persisted in the most recent ART era, including slower suppression among migrant women compared with migrant men. Further disaggregation of sexually acquired HIV revealed additional heterogeneity, particularly between migrant MSM and heterosexual men. These findings highlight the importance of considering the intersection of sex, migration status and HIV acquisition group to better identify population-specific inequalities in HIV care.
- Publisher Full Text (DOI)
- Baseline HIV genotypic resistance testing in patients newly diagnosed with HIV: When do we need to consider baseline integrase resistance testing for everyone? [Journal Article]HIV Med. 2026 Oct 22. [Online ahead of print]HM
- CONCLUSIONS: This manuscript identified a number of cases where baseline integrase resistance was identified. These data suggest that more work is needed to establish whether baseline integrase inhibitor resistance testing is warranted in all individuals newly diagnosed with HIV.
- Publisher Full Text (DOI)
- Understanding community questions about HIV pre-exposure prophylaxis (PrEP): A thematic analysis of reddit threads to inform development of an AI chatbot for PrEP education. [Journal Article]HIV Med. 2026 Oct 20. [Online ahead of print]HM
- CONCLUSIONS: Reddit users demonstrate persistent uncertainty about PrEP side effects, drug interactions and medication switching. Drug interactions represented the most frequently identified information gap (26.5% of posts). These empirically derived information needs will inform the design of a privacy-preserving PrEP chatbot trained on authoritative UK sources (hiv-druginteractions.org, BHIVA guidelines, NHS resources).
- Publisher Full Text (DOI)
- Antiretroviral therapy intensification in people living with HIV on virological and clinical outcomes: A systematic review. [Review]HIV Med. 2026 Oct 18. [Online ahead of print]HM
- CONCLUSIONS: There was no consistent evidence supporting a clear benefit of ART intensification on virological or clinical outcomes. ART intensification outcomes vary according to drug selection, patient characteristics, and treatment goals. These findings highlight the uncertainty surrounding the clinical utility of ART intensification. Further research is needed to optimize intensification strategies for specific patient populations and to better define its role in long-term HIV management.
- Publisher Full Text (DOI)
- Pilot study of a ChatGPT-based educational and counselling tool in a specialist HIV and sexual health clinic. [Journal Article]HIV Med. 2026 Oct 18. [Online ahead of print]HM
- CONCLUSIONS: The pilot implementation of a ChatGPT-based counselling tool in a specialist HIV and sexual health clinic was feasible and generally acceptable to patients and HCWs. Further studies are required to evaluate accuracy and clinical effectiveness before broader implementation.
- Publisher Full Text (DOI)
- Changes in cardiometabolic biomarkers 1 year after direct acting antiviral therapy for hepatitis C virus co-infection among people with HIV. [Journal Article]HIV Med. 2026 Oct 18. [Online ahead of print]HM
- CONCLUSIONS: People with HIV with HCV who initiated DAA demonstrated no statistically significant difference in HbA1c or ASCVD risk score at 12-months compared to HIV/HCV co-infected persons who did no initiate DAA. However, TC and LDL levels increased 12 months following DAA treatment.
- Publisher Full Text (DOI)
- Information quality, understandability, actionability and readability of large language models for HIV health education: A cross-platform evaluation. [Journal Article]HIV Med. 2026 Oct 18. [Online ahead of print]HM
- CONCLUSIONS: LLM-generated HIV patient education materials showed substantial cross-platform and topic-level heterogeneity. These findings support the use of LLMs as expert-reviewed drafting tools rather than independent patient education sources. Direct factual accuracy, guideline concordance, hallucination and clinical safety were not assessed.
- Publisher Full Text (DOI)
- A retrospective cohort study of Ukrainian beneficiaries of temporary protection living with HIV attending an Irish tertiary care service. [Journal Article]HIV Med. 2026 Oct 16. [Online ahead of print]HM
- CONCLUSIONS: Despite timely linkage to care and preserved immune status at enrolment, UBOTPLWH in Ireland experience substantial structural barriers that may adversely affect engagement and virological outcomes. Tailored, accessible service models are required to support displaced populations living with HIV.
- Publisher Full Text (DOI)
- Breastfeeding and HIV in high-income settings: Exploring women living with HIV and health care providers' perspectives in Belgium. [Journal Article]HIV Med. 2026 Oct 16. [Online ahead of print]HM
- CONCLUSIONS: Our findings reveal a gap between women living with HIV's growing openness to breastfeeding and a healthcare workforce not yet fully equipped to support it. Closing this gap will require harmonized protocols, targeted training and culturally sensitive, patient-centred counselling.
- Publisher Full Text (DOI)
- BHIVA Audit 2023: Prior engagement in HIV care among people living with HIV admitted to hospital. [Journal Article]HIV Med. 2026 Oct 15. [Online ahead of print]HM
- CONCLUSIONS: Hospital admissions in people with HIV commonly occur in the context of late diagnosis and sub-optimal engagement in care. Interventions to improve testing, retention and re-engagement, particularly those addressing psychosocial barriers, may help reduce preventable morbidity and support progress towards HIV elimination.
- Publisher Full Text (DOI)
- Hepatitis D virus infection in persons with HIV and hepatitis B virus across Europe: A cross-sectional analysis of the HDV-Europe cohort. [Journal Article]HIV Med. 2026 Oct 15. [Online ahead of print]HM
- CONCLUSIONS: In Europe, about one-eighth of individuals with HIV/HBV in care have evidence of past/current HDV infection, in whom half have active HDV infection. Nevertheless, these results come from a setting where one-quarter have yet to be tested for anti-HDV antibodies.
- Publisher Full Text (DOI)
- A cross-sectional analysis of cardiometabolic and lifestyle-related profiles in men living with HIV in Japan using linked nationwide claims and health checkup data. [Journal Article]HIV Med. 2026 Oct 11. [Online ahead of print]HM
- CONCLUSIONS: Among men receiving contemporary HIV care in Japan, HIV infection was associated with modest differences in BMI and dyslipidaemia but not with hypertension or diabetes mellitus.
- Publisher Full Text (DOI)
- Chronic alanine aminotransferase elevation in people with HIV: Time trends over 22 years and genetic predisposition. [Journal Article]HIV Med. 2026 Oct 11. [Online ahead of print]HM
- CONCLUSIONS: cALT prevalence has decreased by almost half in people with HIV in Switzerland since 2005. Unfavourable genetic background is a strong independent risk factor for cALT.
- Publisher Full Text (DOI)
- Gaps in diabetes care among people living with HIV and hypertension in Botswana: A cross-sectional analysis of the InterCARE study. [Journal Article]HIV Med. 2026 Oct 11. [Online ahead of print]HM
- CONCLUSIONS: Diabetes care among people living with HIV ith hypertension in Botswana is suboptimal with major gaps in screening and metabolic monitoring. These findings highlight broader challenges in the delivery of integrated chronic disease care within HIV services. Strengthening the integration of non-communicable disease care into HIV programmes, including routine diabetes screening and cardiometabolic risk management, is urgently needed to improve health outcomes and reduce the burden of cardiovascular and other chronic complications among people living with HIV.
- Publisher Full Text (DOI)
- A systematic review of evidence on weight change following initiation of long-acting cabotegravir for the prevention or treatment of HIV. [Review]HIV Med. 2026 Oct 08. [Online ahead of print]HM
- CONCLUSIONS: CAB-LA-based regimens were associated with only small increases in weight in both the prevention and treatment of HIV, with no consistent evidence of excess weight gain relative to standard comparators. Continued monitoring will be important as long-acting antiretroviral therapies are scaled up, particularly among women and individuals from Africa.
- Publisher Full Text (DOI)